At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 240 enrolled
Drug / intervention
Erenumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 4, Open-label Study to Evaluate Treatment Satisfaction With Erenumab in Patients With Migraine
In Brief
A Phase 4 clinical trial evaluating Erenumab for Migraine. Completed, enrolled 240 participants across 42 sites.
Detailed Summary
The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartJun 2021
Primary CompletionSep 2023
TodayJul 2026
First PostedApr 1, 2021
Enrollment StartJun 11, 2021
Primary CompletionSep 28, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.3 years ago
Interventions
Erenumabdrug
Administered as a subcutaneous injection via the SureClick® Autoinjector Pen (AI/Pen).